Przegla̜d Gastroenterologiczny
Cure8 research brief
Why This Matters
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin M (OSM) was associated with higher likelihood of response to infliximab or adalimumab.
If validated, OSM testing could reduce trial-and-error when starting anti-TNF therapy.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis considering or starting anti-TNF biologics (infliximab, adalimumab); gastroenterologists and IBD clinicians; researchers studying predictive biomarkers for biologic response.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthFull source text
What To Know
The study suggests baseline serum OSM may help predict who responds to anti-TNF drugs. Measurements were done with a commercial ELISA and statistical performance (AUC) is reported for the full cohort and for CD and UC subgroups.
The study enrolled patients treated with infliximab or adalimumab at a single center in Warsaw between 2018–2019; prior biologic exposure was allowed. Clinical response definitions, treatment schedules, and statistical methods are described in the paper.
This is a single study and not a treatment recommendation; clinicians would need to consider replication, assay standardization, and how OSM testing would fit with current practice before changing care.
Keep In Mind
This is a single-center clinical study with 135 patients; results need independent validation and assay standardization before clinical use. The article reports a specific ELISA method and a proposed cutoff; clinical labs may not currently offer validated OSM testing. The study design, inclusion criteria, and prior biologic exposure may affect generalizability.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPrzegla̜d Gastroenterologiczny
Study typeResearch Article, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Changes in Serum MMP-9 and TIMP-1 Concentrations in Children with Inflammatory Bowel Disease over a Six-Month Observation Period
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...